Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with moderately-to-severely active ulcerative colitis-MedSci.cn

Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with moderately-to-severely active ulcerative colitis

D'Haens, GGR; Sandborn, WJ; Ferrante, M; Bhandari, BR; Berliba, E; Hibi, T; Tuttle, J; Canavan, JB; Friedrich, S; Durante, M; Arora, V; Feagan, B

JOURNAL OF CROHNS & COLITIS, 2019; 13 (): S26

科室
- - 订阅+
  - 更多科室
工具
服务